I think it’s just that the bivalent booster was targeting (a) an extinct variant and (b) a different Omicron subvariant. This will target some form of Omicron XBB, I think, which has been the dominant strain for months now.
You are not logged in. However you can subscribe from another Fediverse account, for example Lemmy or Mastodon. To do this, paste the following into the search field of your instance: !news@beehaw.org
Breaking news from around the world.
News that is American but has an international facet may also be posted here.
Guidelines for submissions:
Where possible, post the original source of information.
If there is a paywall, you can use alternative sources or provide an archive.today, 12ft.io, etc. link in the body.
Do not editorialize titles. Preserve the original title when possible; edits for clarity are fine.
Do not post ragebait or shock stories. These will be removed.
Do not post tabloid or blogspam stories. These will be removed.
Social media should be a source of last resort.
These guidelines will be enforced on a know-it-when-I-see-it basis.
So a monovalent booster should not wane in effectiveness as the bivalent?
I think it’s just that the bivalent booster was targeting (a) an extinct variant and (b) a different Omicron subvariant. This will target some form of Omicron XBB, I think, which has been the dominant strain for months now.